CN109694840A - 一株变形假单胞菌abc转运蛋白基因沉默菌株 - Google Patents
一株变形假单胞菌abc转运蛋白基因沉默菌株 Download PDFInfo
- Publication number
- CN109694840A CN109694840A CN201910012999.4A CN201910012999A CN109694840A CN 109694840 A CN109694840 A CN 109694840A CN 201910012999 A CN201910012999 A CN 201910012999A CN 109694840 A CN109694840 A CN 109694840A
- Authority
- CN
- China
- Prior art keywords
- bacterial strain
- pseudomonad
- gene
- deformation
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000030279 gene silencing Effects 0.000 title claims abstract description 39
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 32
- 238000012226 gene silencing method Methods 0.000 title claims abstract description 20
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title claims abstract description 18
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 title claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 241000251468 Actinopterygii Species 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 12
- 238000013518 transcription Methods 0.000 claims abstract description 6
- 230000035897 transcription Effects 0.000 claims abstract description 6
- 241000248484 Ichthyophthirius Species 0.000 claims abstract description 5
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000004055 small Interfering RNA Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims description 4
- 238000000137 annealing Methods 0.000 claims description 3
- 230000005611 electricity Effects 0.000 claims description 2
- 239000013535 sea water Substances 0.000 claims description 2
- 238000012358 sourcing Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 230000001018 virulence Effects 0.000 abstract description 5
- 210000001835 viscera Anatomy 0.000 abstract description 5
- 229940031567 attenuated vaccine Drugs 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 241000357444 Epinephelus coioides Species 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000010365 information processing Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 208000032536 Pseudomonas Infections Diseases 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241001596950 Larimichthys crocea Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001263448 Mycetozoa Species 0.000 description 1
- 241001223182 Pseudomonas plecoglossicida Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241001417495 Serranidae Species 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明提供一株变形假单胞菌ABC转运蛋白基因沉默菌株,所述菌株为Pseudomonas plecoglossicida ABC‑shRNA‑RNAi,已于2018年11月12日于中国典型培养物保藏中心保藏,保藏号为CCTCC NO:M2018771,本发明通过比较转录组学分析技术,结合RNA干扰这一定向高效的基因沉默技术,构建一株变形假单胞菌ABC转运蛋白基因(L321_23611)稳定沉默菌株,并对该菌株的毒力效果进行检测。所构建的变形假单胞菌L321_23611基因稳定沉默菌株不仅可用于研究变形假单胞菌的致病机理,还可用于研制变形假单胞菌的弱毒疫苗并为海水鱼“内脏白点病”的预防和治疗寻找新的靶点。
Description
技术领域
本发明属于微生物技术领域,更具体涉及一株变形假单胞菌ABC转运蛋白基因沉默菌株。
背景技术
变形假单胞菌(Pseudomonas plecoglossicida)是大黄鱼、斜带石斑鱼等海水养殖鱼类“内脏白点病”的病原菌,每年造成的直接经济损失超亿元。
ABC转运蛋白(ATP Binding Cassette transporters)是一个成员众多的膜蛋白超家族。从细菌到人类,它们通过细胞膜的渗透性屏障运输分子。运输的分子类型极其多样化,从离子、小到中型分子(糖、氨基酸、脂质、离子金属)到大且笨重的化合物(多肽、蛋白质、有机金属复合物和抗生素)。它们参与了许多重要的生理过程,如营养导入、细胞解毒、脂质稳态、信号转导、抗病毒防御和抗原表达。原核生物中,既存在向内转运蛋白又存在向外转运蛋白,这些蛋白在多种生理过程中都发挥着重要的作用。这些蛋白的失活会对细胞的生存产生致命的影响。许多ABC转运蛋白在特定条件下,对细菌的生存能力、毒性以及致病性有着重要的影响。ABC转运蛋白还可以介导铁的运输,这一作用对微生物的毒性有着重要的作用。
本发明通过比较转录组学分析技术,结合RNA干扰这一定向高效的基因沉默技术,构建一株变形假单胞菌ABC转运蛋白基因(L321_23611)稳定沉默菌株,并对该菌株的毒力效果进行检测。所构建的变形假单胞菌L321_23611基因稳定沉默菌株不仅可用于研究变形假单胞菌的致病机理,还可用于研制变形假单胞菌的弱毒疫苗并为海水鱼“内脏白点病”的预防和治疗寻找新的靶点。
发明内容
本发明的目的在于提供一株变形假单胞菌ABC转运蛋白基因沉默菌株。
为实现上述目的,本发明采用如下技术方案:
一株变形假单胞菌ABC转运蛋白基因沉默菌株,所述菌株为Pseudomonas plecoglossicida ABC-shRNA-RNAi,已于2018年11月12日于中国典型培养物保藏中心保藏,保藏号为CCTCC NO:M2018771,地址为中国武汉,武汉大学。
本发明提供的这株变形假单胞菌L321_23611基因稳定沉默菌株是通过以下方法进行构建:
(1)通过比较转录组学分析技术,将筛选致病功能基因目标锁定L321_23611基因;所述的L321_23611基因序列如SEQ ID NO.1所示。
(2)合成shRNA,退火后连入pCM130/tac载体,通过电转技术导入变形假单胞菌感受态细胞,构建变形假单胞菌L321_23611基因稳定沉默菌株;利用QPCR技术,对沉默效果进行检验;所述的pCM130/tac载体是利用质粒pCM130加上启动子tac构成。
(3)利用人工感染实验,研究变形假单胞菌野生株、L321_23611基因沉默株的毒力,以及L321_23611基因沉默对变形假单胞菌及斜带石斑鱼基因表达的影响。
(4)通过基因测序和比对,本发明提供的菌株为一株变形假单胞菌L321_23611基因(ABC转运蛋白基因)稳定沉默菌株。
本发明的优点在于:
人工感染实验结果表明,变形假单胞菌L321_23611基因稳定沉默菌株的毒力显著低于变形假单胞菌野生株的毒力,具有研制减毒疫苗的潜力。
Dual RNA-seq分析结果表明,L321_23611基因的稳定沉默不仅能够显著影响变形假单胞菌的转录组表达,而且也能显著影响斜带石斑鱼的转录组表达,这说明变形假单胞菌L321_23611基因稳定沉默菌株可用于研究变形假单胞菌的致病机理,还可用于为海水鱼“内脏白点病”的预防和治疗寻找新的靶点。
附图说明
图1 斜带石斑鱼感染变形假单胞菌后的存活率图。
图2变形假单胞菌感染斜带石斑鱼组织示意图。
图3斜带石斑感染后脾脏组织的病症变化图。a组为阴性对照,仅注射PBS,b组为阳性对照,用变形假单胞菌野生株进行注射感染,c组为实验组,用L321_23611基因沉默株进行注射感染。
具体实施方式
实施例1
本发明实施例提供的变形假单胞菌L321_23611基因稳定沉默菌株的构建方法包括以下步骤:
S101:通过比较转录组学分析技术,对变形假单胞菌基因表达水平进行检测;利用组学技术,极大的缩小研究范围挑选出最具有研究价值的致病功能基因,ABC转运蛋白(ATPBinding Cassette transporters)是一个成员众多的膜蛋白超家族。许多ABC转运蛋白在特定条件下,对细菌的生存能力、毒性以及致病性有着重要的影响。ABC转运蛋白还可以介导铁的运输,这一作用对微生物的毒性有着重要的作用。转录组测序发现L321_23611基因在变形菌致病温度18°下显示显著高表达(L321_23611基因RNA的测序值18°为1,12°为0.9549,28°为0.3369),故将目标瞄准L321_23611基因;
S102:利用Thermo-fisher Scientific 公司在线shRNA设计工具(http://rnaidesigner.thermofisher.com/rnaiexpress/setOption.dodesignOption=shrna&pid=708587103220684543),设计并合成shRNA,然后使用退火缓冲液退火形成双链shRNA。shRNA序列F:5’-TGCAACTATGGCGAAGTGTTCGTTCAAGAGACGAACACTTCGCCATAGTTGCTTTTTTT-3’,R:5’-GTACAAAAAAAGCAACTATGGCGAAGTGTTCGTCTCTTGAACGAACACTTCGCCATAGTTGCATGCA-3’,从百奥迈科公司购买原始质粒pCM130加上去的启动子tac,构成pCM130/tac质粒。买使用限制性内切酶BsrGI和 NsiI双酶切pCM130/tac质粒使其线性化,然后使用T4连接酶将线性化质粒和双链shRNA连接。将重组质粒先热击转化进大肠杆菌DH5α感受态细胞中,37℃扩大培养,测序成功后提取重组质粒,电击转化进变形假单胞菌感受态细胞中,18℃条件下扩大培养。此菌株即为变形假单胞菌L321_23611基因沉默突变株。所述变形假单胞菌L321_23611基因沉默突变株为Pseudomonas plecoglossicida ABC-shRNA-RNAi,已于2018年11月12日于中国典型培养物保藏中心保藏,保藏号为CCTCC NO:M2018771。
使用qRT-PCR技术,对沉默效果进行检验,上游引物序列(5’-3’’)为:GCGACGGTCTTCCAGGCTTCT ,下游引物序列(5’-3’’)为:GCTGGCTGAACTTGACCTTGCTG; 检验结果与转录组测序结果一致,感染后L321_23611基因表达量上调;
S103:利用人工感染实验,对变形假单胞菌野生株和L321_23611基因沉默株的毒力进行对比。
L321_23611基因沉默株、变形假单胞菌野生株和PBS(NaCl 0.8g、KCl 0.02g、Na2HPO4 0.36g、 KH2PO4 0.024g、H2O 1L)分别对三组斜带石斑鱼进行胸腔注射感染,菌株感染浓度为103cfu/g,每条鱼注射0.2 mL,每组20尾鱼,然后继续正常暂养,并记录每天各组鱼的存活状况。
变形假单胞菌L321_23611基因沉默株与野生株感染斜带石斑鱼后,斜带石斑鱼的存活情况如图1所示,与野生株相比,沉默株推迟一天出现死亡现象;在第五天时,沉默株的死亡率比野生株的死亡率降低了32%;野生株的斜带石斑鱼在第六天时全部死亡,而沉默株的实验用鱼在第七天后不再出现死亡现象。
解剖经过变形假单胞菌注射感染后的斜带石斑鱼,变形假单胞菌感染斜带石斑鱼组织示意图如图2所示,观察后发现,在头肾、体肾、肝脏和脾脏中,内脏白点最明显的部位是脾脏。对脾脏部位的跟踪拍摄,结果如图3所示,a组为PBS注射,为阴性对照,脾脏没有发生明显病变,属于正常脾脏状态;b组为野生株注射 ,为阳性对照,脾脏从第三天开始出现白点现象,症状逐渐严重,第六天该组实验用鱼全部死亡。c组为沉默株注射,为实验组,脾脏出现白点现象的时间比野生株推迟一天,症状也是逐渐严重,但总体而言,症状没有阳性对照组的症状严重。
在对变形假单胞菌进行斜带石斑鱼活体感染的过程中发现,沉默株相比于野生株的死亡时间有所推迟,在实验结束时,野生株的试验用鱼全部死亡,而沉默株的试验用鱼最终存活率为8%,同时阴性对照组的所有试验用鱼全部存活。感染过程中对主要感染器官——脾脏进行跟踪观察,发现阴性对照没有明显的病变现象,野生株的脾脏在第三天时出现白点症状并逐渐严重,而沉默株的病变现象相对于野生株而言,出现的时间较晚,症状较轻。实验结果与他人的研究成果相互印证,证明变形假单胞菌确实对斜带石斑鱼有致病性,L321_23611基因对该细菌的致病性有显著影响。
S104:利用dual RNA-seq技术对L321_23611基因沉默株和野生株变形假单胞菌感染后的斜带石斑鱼的脾脏进行转录组测序,比较分析L321_23611基因的沉默对变形假单胞菌和斜带石斑鱼基因表达的影响。
通过转录组测序对变形假单胞菌与斜带石斑鱼进行了大规模的转录组学分析,从而研究二者之间的互作过程。我们总共测得4914个变形假单胞菌的差异基因,183843个斜带石斑鱼的差异基因,通过对这些差异基因进行GO富集分析和KEGG富集分析。将细菌中的差异基因富集到KEGG通路上,结果发现,按照第一大分类方式,差异基因按数量分别富集到了新陈代谢(Metabolism,65%)、遗传信息处理(Genetic Information Processing,11%)、人类疾病(Human Diseases,11%)、环境信息处理(Environmental InformationProcessing,7%)、细胞过程(Cellular Processes,4%)、生物系统(Organismal Systems,2%)六大生化代谢途径中。对病原菌而言,聚集到新陈代谢上的差异基因数目具有显著优势,说明了L321_23611基因在进行跨膜运输过程中在各种物质转运上扮演重要角色。
表1细菌差异表达基因KEGG显著性富集结果
将宿主的差异基因富集到KEGG通路上,结果发现,按照第一大分类方式,差异基因按数量依次富集到了新陈代谢(31.69%)、人类疾病(22.77%)、生物系统(22.46%)、环境信息处理(10.46%)、遗传信息处理(6.15%)、细胞过程(4.92%)六大生化代谢途径。对宿主而言,聚集到信号转导和免疫系统上的差异基因具有显著优势,证明病原菌在进入宿主体内后,引起了宿主的应激反应,宿主调动体内的各项防御措施,抵制病原菌对其产生的影响。
表2宿主差异表达基因KEGG显著性富集结果
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
SEQUENCE LISTING
<110> 集美大学
<120> 一株变形假单胞菌ABC转运蛋白基因沉默菌株
<130> 5
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 1029
<212> DNA
<213> 人工序列
<400> 1
atgaagatgt tgaaaaccac cctggcagtc ctgaccgctg ccgccgcact gggcgccgtg 60
agcactgccc aggccggcgc cacactcgat gcggtaaaga agaagggctt cgtccagtgt 120
ggcgtgagcg acggtcttcc aggcttctcg gtccctgatg cgcagggcaa gatcgtcggt 180
atcgatgccg atgtctgccg cgccgtggct gctgccgtgt tcggcgacgc cagcaaggtc 240
aagttcagcc agctcaacgc caaggagcgc ttcaccgcct tgcaatccgg cgaagtcgac 300
gtgctgtcgc gcaacaccac ctggaccagc tcgcgcgatg ccggcatggg cctggtgttc 360
gccggcgtca cctactacga cggcgttggc ttcctggtca acaagaagct cggcgtctcc 420
agcgccaagg aactcgatgg cgcgaccatc tgcatccagg ccggtaccac caccgaactg 480
aacgtgtccg acttcttccg tgccaacggc ctgaaataca ccccgatcac cttcgacacc 540
tccgacgaaa gcgccaagtc gctggaatcg ggccgttgcg acgtgctgac ctcggacaag 600
tcgcagctgt tcgcccagcg ctccaagctg gccgcaccga ccgagtatgt ggtgctgccg 660
gagaccatct ccaaggaacc gctgggcccg gtggtgcgca agggcgacga ggaatggttc 720
agcatcgtca agtggaccct gttcgccatg ctcaatgccg aagaggcggg catcacctcg 780
aagaacgtcg aggccgaagc caagggcacc aagaacccgg acgtcgctcg cctgctcggt 840
gccgacggtg aatacggcaa ggacctgaaa ctgcccaagg actgggtggt gcagatcgtc 900
aagcaggtcg gcaactatgg cgaagtgttc gagaagaacc tgggccagag caccgacctg 960
aagatcgacc gtggcatgaa cgccctgtgg aacaacggcg gcatccagta cgcgccacct 1020
gtgcgctga 1029
<210> 2
<211> 59
<212> DNA
<213> 人工序列
<400> 2
tgcaactatg gcgaagtgtt cgttcaagag acgaacactt cgccatagtt gcttttttt 59
<210> 3
<211> 67
<212> DNA
<213> 人工序列
<400> 3
gtacaaaaaa agcaactatg gcgaagtgtt cgtctcttga acgaacactt cgccatagtt 60
gcatgca 67
<210> 4
<211> 21
<212> DNA
<213> 人工序列
<400> 4
gcgacggtct tccaggcttc t 21
<210> 5
<211> 23
<212> DNA
<213> 人工序列
<400> 5
gctggctgaa cttgaccttg ctg 23
Claims (5)
1.一株变形假单胞菌ABC转运蛋白基因沉默菌株,其特征在于:所述菌株为Pseudomonas plecoglossicida ABC-shRNA-RNAi,已于2018年11月12日于中国典型培养物保藏中心保藏,保藏号为CCTCC NO:M2018771。
2.如权利要求1所述的一株变形假单胞菌ABC转运蛋白基因沉默菌株的构建方法,其特征在于:所述方法包括如下:
(1)通过比较转录组学分析技术,将筛选致病功能基因目标锁定L321_23611基因;
(2)合成shRNA,退火后连入pCM130/tac载体,通过电转技术导入变形假单胞菌感受态细胞,构建变形假单胞菌L321_23611基因稳定沉默菌株;利用QPCR技术,对沉默效果进行检验,最终获得所述的变形假单胞菌ABC转运蛋白基因沉默菌株。
3.根据权利要求2所述的一株变形假单胞菌ABC转运蛋白基因沉默菌株的构建方法,其特征在于:所述的L321_23611基因序列如SEQ ID NO.1所示。
4.根据权利要求2所述的一株变形假单胞菌ABC转运蛋白基因沉默菌株的构建方法,其特征在于:所述的pCM130/tac载体是利用质粒pCM130加上启动子tac构成。
5.如权利要求1所述的一株变形假单胞菌ABC转运蛋白基因沉默菌株在制备预防和治疗海水鱼内脏白点病制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910012999.4A CN109694840B (zh) | 2019-01-07 | 2019-01-07 | 一株变形假单胞菌abc转运蛋白基因沉默菌株 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910012999.4A CN109694840B (zh) | 2019-01-07 | 2019-01-07 | 一株变形假单胞菌abc转运蛋白基因沉默菌株 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109694840A true CN109694840A (zh) | 2019-04-30 |
CN109694840B CN109694840B (zh) | 2020-11-06 |
Family
ID=66232517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910012999.4A Expired - Fee Related CN109694840B (zh) | 2019-01-07 | 2019-01-07 | 一株变形假单胞菌abc转运蛋白基因沉默菌株 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109694840B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112625996A (zh) * | 2021-02-04 | 2021-04-09 | 集美大学 | 一株变形假单胞菌znuA基因稳定沉默菌株及应用 |
CN112662608A (zh) * | 2021-02-04 | 2021-04-16 | 集美大学 | 一株变形假单胞菌exbB基因稳定沉默菌株及应用 |
CN113528407A (zh) * | 2021-05-31 | 2021-10-22 | 集美大学 | 一株变形假单胞菌tonB基因沉默菌株及其应用 |
CN114703115A (zh) * | 2022-04-22 | 2022-07-05 | 集美大学 | 一种变形假单胞菌fliS基因沉默菌株和用途 |
-
2019
- 2019-01-07 CN CN201910012999.4A patent/CN109694840B/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112625996A (zh) * | 2021-02-04 | 2021-04-09 | 集美大学 | 一株变形假单胞菌znuA基因稳定沉默菌株及应用 |
CN112662608A (zh) * | 2021-02-04 | 2021-04-16 | 集美大学 | 一株变形假单胞菌exbB基因稳定沉默菌株及应用 |
CN112662608B (zh) * | 2021-02-04 | 2022-06-10 | 集美大学 | 一株变形假单胞菌exbB基因稳定沉默菌株及应用 |
CN112625996B (zh) * | 2021-02-04 | 2022-06-10 | 集美大学 | 一株变形假单胞菌znuA基因稳定沉默菌株及应用 |
CN113528407A (zh) * | 2021-05-31 | 2021-10-22 | 集美大学 | 一株变形假单胞菌tonB基因沉默菌株及其应用 |
CN113528407B (zh) * | 2021-05-31 | 2023-01-10 | 集美大学 | 一株变形假单胞菌tonB基因沉默菌株及其应用 |
CN114703115A (zh) * | 2022-04-22 | 2022-07-05 | 集美大学 | 一种变形假单胞菌fliS基因沉默菌株和用途 |
CN114703115B (zh) * | 2022-04-22 | 2023-09-29 | 集美大学 | 一种变形假单胞菌fliS基因沉默菌株和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN109694840B (zh) | 2020-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109694840A (zh) | 一株变形假单胞菌abc转运蛋白基因沉默菌株 | |
Pinski et al. | Defining the genetic basis of plant–endophytic bacteria interactions | |
Sheibani-Tezerji et al. | The genomes of closely related Pantoea ananatis maize seed endophytes having different effects on the host plant differ in secretion system genes and mobile genetic elements | |
Joardar et al. | Whole-genome sequence analysis of Pseudomonas syringae pv. phaseolicola 1448A reveals divergence among pathovars in genes involved in virulence and transposition | |
Bart et al. | High-throughput genomic sequencing of cassava bacterial blight strains identifies conserved effectors to target for durable resistance | |
CN110055200A (zh) | 一株变形假单胞菌clpV基因沉默菌株 | |
López-Pérez et al. | Evolutionary model of cluster divergence of the emergent marine pathogen Vibrio vulnificus: from genotype to ecotype | |
Liu et al. | Contributions of the oligopeptide permeases in multistep of Vibrio alginolyticus pathogenesis | |
Frąckowiak et al. | Assessment of the efficacy and mode of action of benzo (1, 2, 3)-thiadiazole-7-carbothioic acid s-methyl ester (bth) and its derivatives in plant protection against viral disease | |
CN109652357B (zh) | 细胞共培养下生长缺陷的牛支原体突变株及应用 | |
Yang et al. | Prophage-related gene VpaChn25_0724 contributes to cell membrane integrity and growth of Vibrio parahaemolyticus CHN25 | |
Puigvert et al. | Transcriptomes of Ralstonia solanacearum during root colonization of Solanum commersonii | |
Xin et al. | Integration of RNA-seq and RNAi provides a novel insight into the effect of pvdE gene to the pathogenic of Pseudomonas plecoglossicida and on the immune responses of orange-spotted grouper (Epinephelus coioides) | |
He et al. | Integration of RNA‐seq and RNAi reveals the contribution of znuA gene to the pathogenicity of Pseudomonas plecoglossicida and to the immune response of Epinephelus coioides | |
Guo et al. | Biological characteristics and genetic evolutionary analysis of emerging pathogenic Bacillus cereus isolated from Père David's deer (Elaphurus davidianus) | |
Akremi et al. | First report of filamentous phages isolated from Tunisian orchards to control Erwinia amylovora | |
He et al. | Copper stress by nutritional immunity activates the CusS-CusR two-component system that contributes to Vibrio alginolyticus anti-host response but affects virulence-related properties | |
Yin et al. | A specific antimicrobial protein CAP-1 from Pseudomonas sp. isolated from the jellyfish Cyanea capillata | |
Brouwer et al. | Transcriptome analysis of potato infected with the necrotrophic pathogen Alternaria solani | |
Wiehlmann et al. | Functional genomics of Pseudomonas aeruginosa to identify habitat-specific determinants of pathogenicity | |
Han et al. | Stress response, amino acid biosynthesis and pathogenesis genes expressed in Salmonella enterica colonizing tomato shoot and root surfaces | |
Strauch et al. | Predatory mechanisms of Bdellovibrio and like organisms | |
Dias et al. | Vibrio tapetis displays an original type IV secretion system in strains pathogenic for Bivalve molluscs | |
Tang et al. | The contribution of exbB gene to pathogenicity of Pseudomonas plecoglossicida and its interactions with Epinephelus coioides | |
Guan et al. | Transcriptomic and functional analyses reveal roles of AclR, a LuxR-type global regular, in regulating motility and virulence of Acidovorax citrulli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201106 |